CD117 IHC

This measurement helps determine the presence or absence of CD117 in tumours, which can provide valuable information for diagnostic and treatment purposes.

• To diagnose and monitor gastrointestinal stromal tumours (GIST), seminomas, and melanomas 
• Help determine the stage of GISTs and melanomas
• To evaluate the effectiveness of treatment for these types of tumours
• Detect recurrence of GISTs, seminomas, and melanomas

• This test is recommended for patients with suspected or diagnosed GIST, seminoma, or melanoma.
• It may be advised if you have specific symptoms suggestive of these tumours, such as a mass or lump, abnormal pain, or abnormal growth, and change in the size, shape, or color of a mole.
• A family history of GISTs, seminomas, or melanomas
• Patients already receiving treatment for these tumours may undergo this test to assess treatment effectiveness.

Abnormal results could be a strong indication that GISTs, seminomas, or melanomas are present. However, a positive test result does not necessarily mean that you have GISTs, seminomas, or melanomas. Other conditions can also cause a positive result, such as reactive hyperplasia or granulomas.

• Your doctor will collect a small sample from your tumour using a biopsy or excision procedure.
• The sample will be sent to a laboratory for analysis.
• The laboratory will perform immunohistochemistry (IHC) testing to determine CD117 expression in the tumour.

• You may need to provide the original histopathology report, clinical details, and relevant radiological information.
• Ensure that the tumour sample is properly preserved in a paraffin block (formalin-fixed paraffin-embedded).
• Follow any other specific instructions provided by your healthcare provider.

• Histology and IHC testing: These tests help analyse the characteristics of the tumour and identify specific protein expressions. 
• Flow cytometry: This test examines cells from the blood or lymph nodes to see if they have the characteristics of GISTs, seminomas, or melanoma cells.
• Molecular testing: This may be suggested to determine additional genetic alterations or mutations in the tumour.
• Radiological imaging: Scans like CT scans or MRIs may be used to locate and evaluate the extent of the tumour.

IHC single marker with reporting CD117 or C-kit

GIST stands for gastrointestinal stromal tumour. It is a type of cancer that originates from special cells in the wall of the gastrointestinal tract. GISTs can occur anywhere along the digestive tract, commonly in the stomach or small intestine.